Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?

Imagem de Miniatura
Arquivos
art_LORENZI_Can_the_careHPV_test_performed_in_mobile_units_2016.PDF (191.73 KB)
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
LORENZI, Adriana T.
FREGNANI, Jose Humberto T.
POSSATI-RESENDE, Julio Cesar
ANTONIAZZI, Marcio
SCAPULATEMPO-NETO, Cristovam
SYRJANEN, Stina
Citação
CANCER CYTOPATHOLOGY, v.124, n.8, p.581-588, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUNDHuman papillomavirus (HPV) DNA testing can be crucial for women who have limited access to traditional screening. The current study compared the results obtained through HPV DNA testing with those obtained through cytology-based screening. METHODSA total of 3068 women aged 18 to 85 years were enrolled in an opportunistic cervical cancer screening program developed by the Barretos Cancer Hospital and performed by a team of health professionals working within a mobile unit from March to December 2012, followed by statistical analyses. For each patient, 2 different cervical samples were collected and preserved in a careHPV assay and SurePath medium, respectively. RESULTSHigh-risk HPV (hr-HPV) DNA was detected in 10.0% of women, with the majority (86.7%) demonstrating no abnormal Papanicolaou test results. The following cytological samples were found to be hr-HPV positive: 8.2% of the normal samples; 39.4% of the samples with atypical squamous/glandular cells of undetermined significance; 38.5% of the samples with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion; 55.3% of the samples with low-grade squamous intraepithelial lesions; and 100% of the samples with high-grade squamous intraepithelial lesions. Colposcopy examinations were performed among 33.4% of the women with positive results on at least 1 of the tests (HPV DNA positive and/or cytology with atypical squamous/glandular cells of undetermined significance, cannot exclude high-grade lesion or high-grade squamous intraepithelial lesions), and 59.5% of these women underwent biopsies. Among these samples, 18.2% were confirmed as cervical intraepithelial neoplasia. CONCLUSIONSThe careHPV test was demonstrated to be a feasible alternative to primary screening in low-resource settings accessed through the use of mobile units. Cancer Cytopathol 2016;124:581-8. (c) 2016 American Cancer Society. The human papillomavirus (HPV) DNA test is an important tool that is used to improve screening programs. The HPV DNA test allows for the detection of early HPV-induced lesions in women, thereby enabling clinicians to provide the best possible follow-up.
Palavras-chave
cancer screening, cervical cancer, colposcopy, human papillomavirus (HPV) DNA tests, Papanicolaou test
URI
https://observatorio.fm.usp.br/handle/OPI/17047
Referências
  1. Arbyn M, 2012, VACCINE, V30, pF88, DOI 10.1016/j.vaccine.2012.06.095
  2. Ayres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
  3. Becker E, 2001, DIAGN CYTOPATHOL, V24, P276, DOI 10.1002/dc.1059
  4. Campos NG, 2014, AM J EPIDEMIOL, V180, P545, DOI 10.1093/aje/kwu159
  5. Castle PE, 2012, J CLIN ONCOL, V30, P3044, DOI 10.1200/JCO.2011.38.8389
  6. Castle PE, 2012, VACCINE, V30, pF117, DOI 10.1016/j.vaccine.2012.05.071
  7. Chen W, 2014, J CLIN VIROL, V61, P553, DOI 10.1016/j.jcv.2014.09.018
  8. de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
  9. Diaz ML, 2013, OBSTET GYN CLIN N AM, V40, P391, DOI 10.1016/j.ogc.2013.02.003
  10. Dijkstra MG, 2014, CANCER EPIDEM BIOMAR, V23, P55, DOI 10.1158/1055-9965.EPI-13-0173
  11. Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
  12. Entiauspe LG, 2014, BRAZ J MICROBIOL, V45, P689, DOI [10.1590/S1517-83822014005000047, 10.1590/S1517-83822014000200043]
  13. Fakokunde B, 2008, INT J GYNECOL OBSTET, V101, P245, DOI 10.1016/j.ijgo.2007.11.014
  14. Fernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
  15. Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
  16. Gage JC, 2014, CANCER CYTOPATHOL, V122, P842, DOI 10.1002/cncy.21463
  17. Instituto Nacional do Cancer/National Cancer Institute (INCA), CANC BRAZ DAT POP BA
  18. Jeronimo J, 2015, J LOW GENIT TRACT DI, V19, P220, DOI 10.1097/LGT.0000000000000088
  19. Kang LN, 2014, J CLIN MICROBIOL, V52, P1954, DOI 10.1128/JCM.03432-13
  20. Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS36, DOI 10.1097/LGT.0b013e3182854253
  21. Katki HA, 2013, J LOW GENIT TRACT DI, V17, pS56, DOI 10.1097/LGT.0b013e318285437b
  22. Labani S, 2014, EUR J OBSTET GYN R B, V181, P233, DOI 10.1016/j.ejogrb.2014.08.005
  23. Labani S, 2016, J EPIDEMIOL COMMUN H, V70, P72, DOI 10.1136/jech-2015-205851
  24. Lin CQ, 2014, J VIROL METHODS, V202, P73, DOI 10.1016/j.jviromet.2014.03.002
  25. Longatto-Filho A, 2007, DIAGN CYTOPATHOL, V35, P672, DOI 10.1002/dc.20700
  26. Lorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092
  27. Louvanto K, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.12.033
  28. Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430
  29. Moyer VA, 2012, ANN INTERN MED, V156, P880, DOI 10.7326/0003-4819-156-12-201206190-00424
  30. Nonnenmacher B, 2002, REV SAUDE PUBL, V36, P95, DOI [10.1590/S0034-89102002000100015, 10.1590/s0034-89102002000100015]
  31. Noronha VL, 2011, J BRAS DOENCAS SEX T, V23, P5, DOI 10.5533/2177-8264-201123103
  32. Paengchit K, 2014, ASIAN PAC J CANCER P, V15, P7951, DOI 10.7314/APJCP.2014.15.18.7951
  33. Poljak M, 2012, VACCINE, V30, pF100, DOI 10.1016/j.vaccine.2012.04.105
  34. Qiagen, 2008, CAREHPV TEST TRAIN G
  35. Qiao YL, 2014, INT J CANCER, V134, P2891, DOI 10.1002/ijc.28616
  36. Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9
  37. Rosa MI, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.033
  38. Rositch AF, 2013, INT J CANCER, V133, P1271, DOI 10.1002/ijc.27828
  39. Saayman F, 2013, INT J GYNECOL OBSTET, V120, P257, DOI 10.1016/j.ijgo.2012.09.022
  40. Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516
  41. Saslow D, 2012, CA-CANCER J CLIN, V62, P147, DOI 10.3322/caac.21139
  42. Schiffman M, 2015, J CLIN MICROBIOL, V53, P52, DOI 10.1128/JCM.02116-14
  43. Schmitt FC, 2008, J CLIN PATHOL, V61, P258, DOI 10.1136/jcp.2006.044347
  44. Tahseen S, 2008, EUR J OBSTET GYN R B, V139, P90, DOI 10.1016/j.ejogrb.2007.09.001
  45. de Aguiar SRV, 2014, J MED VIROL, V86, P1528, DOI 10.1002/jmv.23972
  46. World Health Organization, 2014, COMPR CERV CANC CONT
  47. World Health Organization and International Agency for Research on Cancer, CERV CANC EST INC MO
  48. Zhao FH, 2013, CANCER PREV RES, V6, P938, DOI 10.1158/1940-6207.CAPR-13-0091
  49. Zhao FH, 2012, CANCER EPIDEMIOL, V36, P384, DOI 10.1016/j.canep.2012.01.009
  50. Zhao FH, 2012, J NATL CANCER I, V104, P178, DOI 10.1093/jnci/djr532

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03